Trial Profile
A Pilot Study of Second-line Treatment With Apatinib After Trans Arterial Chemoembolization (TACE) in Advanced Hepatocellular Carcinoma Patients
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 06 Apr 2016 New trial record